HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CARES Act Makes Threatened Sunscreen Ingredients GRASE Again, But Next Steps Uncertain

Executive Summary

Many questions remain following the late March enactment of the US CARES Act, which overhauls the FDA’s OTC drug regulatory framework and resets the GRASE status of long-used sunscreen drug ingredients whose safety and effectiveness have come under question at the FDA.

You may also be interested in...



Hawaii Puts Hold On Proposal To Blacklist Additional Sunscreen Ingredients

Proposed bills in the Aloha State would ban the sale of sunscreens containing octocrylene and/or avobenzone, adding to a UV filter blacklist that already includes oxybenzone and octinoxate. On 17 February, Hawaiian legislators elected to defer the legislation to await completion of a National Academy of Sciences study, targeted for 2022.

PCPC Leadership On US Legislative Landscape, EU Microplastic Restriction, Other 2021 Concerns

The Personal Care Products Council’s government affairs heads, chief scientist and executive VP of global strategies discuss the trade association’s 2021 priorities and preoccupations.

US Consumer Health 2020 News: ’60 Minutes’ Probiotic Dip Tops Switches, Monograph, Pandemic

Supplement industry’s bullseye on “60 Minutes” after its June segment critical of probiotic health benefits generated the most reads for a US consumer health and overall for HBW Insight articles in 2020. Articles about COVID-19 enforcement actions weren’t as widely read as coverage of FDA’s reorganization in its OTC drug offices and its approvals of additional ingredients to be available OTC.

Related Content

Topics

UsernamePublicRestriction

Register

RS149919

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel